LUPIN Stock Overview
A pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Lupin Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,621.35 |
| 52 Week High | ₹1,728.00 |
| 52 Week Low | ₹884.25 |
| Beta | 0.60 |
| 11 Month Change | 1.24% |
| 3 Month Change | 0.28% |
| 1 Year Change | 79.60% |
| 33 Year Change | 39.71% |
| 5 Year Change | 120.38% |
| Change since IPO | 20,028.49% |
Recent News & Updates
These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely
Jun 15
Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results
May 09With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case
May 08Recent updates
These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely
Jun 15Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results
May 09With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case
May 08Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking
Apr 20Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly
Mar 03Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 10Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk
Jan 19Is Lupin (NSE:LUPIN) Using Too Much Debt?
Nov 10Is Lupin (NSE:LUPIN) Using Too Much Debt?
Jun 23Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly
Mar 24Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00
Jul 08Is Lupin Limited (NSE:LUPIN) Worth ₹756 Based On Its Intrinsic Value?
Mar 27Lupin (NSE:LUPIN) Could Easily Take On More Debt
Jan 22Shareholder Returns
| LUPIN | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.9% | 0.9% | 1.1% |
| 1Y | 79.6% | 46.8% | 44.4% |
Return vs Industry: LUPIN exceeded the Indian Pharmaceuticals industry which returned 46.8% over the past year.
Return vs Market: LUPIN exceeded the Indian Market which returned 45.2% over the past year.
Price Volatility
| LUPIN volatility | |
|---|---|
| LUPIN Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: LUPIN has not had significant price volatility in the past 3 months.
Volatility Over Time: LUPIN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 20,933 | Vinita Gupta | www.lupin.com |
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women’s health, and anti-tuberculosis. The company is also involved in the provision of biosimilars; over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities.
Lupin Limited Fundamentals Summary
| LUPIN fundamental statistics | |
|---|---|
| Market cap | ₹739.11b |
| Earnings (TTM) | ₹19.14b |
| Revenue (TTM) | ₹200.11b |
38.6x
P/E Ratio3.7x
P/S RatioIs LUPIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LUPIN income statement (TTM) | |
|---|---|
| Revenue | ₹200.11b |
| Cost of Revenue | ₹66.43b |
| Gross Profit | ₹133.67b |
| Other Expenses | ₹114.53b |
| Earnings | ₹19.14b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 41.99 |
| Gross Margin | 66.80% |
| Net Profit Margin | 9.57% |
| Debt/Equity Ratio | 18.6% |
How did LUPIN perform over the long term?
See historical performance and comparison